Three surveillance strategies for vancomycin-resistant enterococci in hospitalized patients: Detection of colonization efficiency and a cost-effectiveness model

Infection Control and Hospital Epidemiology

Volumn 26, Issue 1, 2005, Pages 39-46

  Lee, Todd A ^a,b,e   Hacek, Donna M ^c   Stroupe, Kevin T ^a,b   Collins, Susan M ^d   Peterson, Lance R ^b,c  

^a HINES VA HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^d NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ARTICLE; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE; COST EFFECTIVENESS ANALYSIS; EMERGENCY WARD; FECES ANALYSIS; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; MEDICAL RECORD; MODEL; OUTPATIENT; PROBABILITY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

CARRIER STATE; CLOSTRIDIUM DIFFICILE; COST-BENEFIT ANALYSIS; ENTEROCOCCUS; FECES; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; INFECTION CONTROL; MODELS, ECONOMIC; SENTINEL SURVEILLANCE; VANCOMYCIN RESISTANCE;

EID: 12144254075     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502485     Document Type: Article

References (39)

1. Chavers LS, Moser SA, Benjamin WH, et al. Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect 2003;53:159-171.
2. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-721.
3. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-670.
4. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922-929.
5. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522-527.
6. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362-386.
7. Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19: 539-545.
8. Boyce JM, Mermel LA, Zervos MJ, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995;16:634-637.
9. Byers KE, Anglim AM, Anneski CJ, et al. A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control. Infect Control Hosp Epidemiol 2001;22:140-147.
10. Jochimsen EM, Fish L, Manning K, et al. Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Infect Control Hosp Epidemiol 1999;20:106-109.
11. Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant Enterococcus in health care facilities in a region. N Engl J Med 2001;344:1427-1433.
12. Hacek DM, Bednarz P, Noskin GA, Zembower T, Peterson LR. Yield of vancomycin-resistant enterococci and multidrug-resistant Enterobacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused surveillance program. J Clin Microbiol 2001;39:1152-1154.
13. Brown SD, Washington JA. Evaluation of the Repliscan system for identification of Enterobacteriaceae. J Clin Microbiol 1978;8:695-699.
14. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
15. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290-308.
16. Critchfield GC, Willard KE, Connelly DP. Probabilistic sensitivity analysis methods for general decision models. Comput Biomed Res 1986;19:254-265.
17. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985;5:157-177.
18. Northwestern Memorial Hospital. Northwestern Memorial Healthcare 2001 Annual Report. Chicago: Northwestern Memorial Hospital; 2002.
19. Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001;22:437442.
20. Linden PK, Pasculle AW, Mancz R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22: 663-670.
21. Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003;37:921-928.
22. Jernigan JA, Clemence MA, Stott GA, et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol 1995;16:686-696.
23. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002; 23:429-435.
24. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index for Medical Care. Washington, DC: U.S. Department of Labor, Bureau of Labor Statistics; 2003. Available at www.bls.gov/cpi/home.htm. Accessed December 17, 2004.
25. Illinois Health Care Cost Containment Council. Hospital Care Buyer's Guide for Chicago, IL 2000. Springfield, IL: Illinois Health Care Cost Containment Council; 2000. Available at www.state. il.us/agency/hcccc/freepubs/ hbgch00.pdf. Accessed December 17, 2004.
26. Department of Health and Human Services, Centers for Medicaid and Medicare Services. Prospective Payment System: Standardizing File. Baltimore, MD: Department of Health and Human Services, Centers for Medicaid and Medicare Services; 2001. Available at www.cms.hhs.gov/providers/pufdownload. Accessed on December 17, 2004.
27. Montecalvo MA, Jarvis WR, Uman J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterocooci in an endemic setting. Ann Intern Med 1999;131:269-272.
28. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendation of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44:1-13.
29. Kate KC, Gardam MA, Burt J, Conly JM. A comparison of multifaceted versus Clostridium difficile-focused VRE surveillance strategies in a low-prevalence setting. Infect Control Hosp Epidemiol 2001;22:219-221.
30. Leber AL, Hindler JF, Kato EO, Bruckner DA, Pegues DA. Laboratory-based surveillance for vancomycin-resistant enterococci: utility of screening stool specimens submitted for Clostridium difficile toxin assay. Infect Control Hosp Epidemiol 2001;22:160-164.
31. Rafferty ME, McCormick MI, Bopp LH, et al. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol 1997;18:342-344.
32. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-1034.
33. Hacek DM, Suriano T, Noskin GA, Kruszynski J, Reisberg B, Peterson LR. Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality. Am J Clin Pathol 1999;111:647-654.
34. Peterson LR, Noskin GA. New technology for detecting multidrug-resistant pathogens in the clinical microbiology laboratory. Emerg Infect Dis 2001;7:306-311.
35. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261-266.
36. Lai KK, Kelley AL, Melvin ZS, Belliveau PP, Fontecchio SA. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infect Control Hosp Epidemiol 1998; 19:647-652.
37. Calfee DP, Giannetta ET, Durbin LJ, Germanson TP, Farr BM. Control of endemic vancomycin-resistant Enterococcus among inpatients at a university hospital. Clin Infect Dis 2003;37:326-332.
38. Padiglione AA, Wolfe R, Grabsch EA, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 2003;47:2492-2498.
39. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997; 24(suppl 1):S19-S45.